Enzo Biochem has filed a patent for a compound that can be used to determine the presence of an activator in a sample. The compound consists of a signaling molecule bound to a self-immolative structure, which can be modified by the activator to generate an increased signal. The patent also covers methods for detecting nitroreductase, determining hypoxia in mammalian cells, and identifying nitroreductase in a sample. GlobalData’s report on Enzo Biochem gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Enzo Biochem Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Enzo Biochem, cancer treatment biomarkers was a key innovation area identified from patents. Enzo Biochem's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.

Compound for signal amplification and detection of activators

Source: United States Patent and Trademark Office(USPTO). Credit: Enzo Biochem Inc

A recently filed patent (Publication Number: US20230175036A1) describes a compound with a specific structure that has potential applications in signaling and detection systems. The compound consists of a signaling molecule (SIG) bound to a self-immolative structure (SI) and a moiety (MOD) that can be modified by an activator. The compound is designed in such a way that when the MOD is modified by an activator, the SI is destabilized and cleaved from the SIG, resulting in an increased signal.

The patent claims also specify that the activator in question is a disulfide reducing agent, which can include substances like glutathione, cysteine, or homocysteine. These agents play a crucial role in modifying the MOD and triggering the self-cleavage of SI from SIG, leading to the generation of an amplified signal.

The patent further mentions that the value of m, which represents the number of MOD moieties bound to SI, can range from 1 to about 10. This indicates that the compound can have multiple MOD moieties, potentially enhancing its signal amplification capabilities.

It is worth noting that the patent claims also include variations in the value of m. Claim 120 specifies that m can be greater than 1, allowing for the possibility of multiple MOD moieties. On the other hand, claim 121 states that m can be equal to 1, indicating that the compound can also exist with a single MOD moiety.

Overall, this patent presents a compound with a unique structure that can be activated by a disulfide reducing agent to generate an increased signal. The compound's design allows for flexibility in the number of MOD moieties, potentially offering versatility in signal amplification. This innovation could have significant implications in various fields, including signaling and detection systems.

To know more about GlobalData’s detailed insights on Enzo Biochem, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies